Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modern therapy for inflammatory bowel disease.

P Rutgeerts1

  • 1Dept. of Medicine, University Hospital Leuven, Belgium. paul.rutgeerts@uz.kuleuven.ac.be

Scandinavian Journal of Gastroenterology. Supplement
|June 12, 2003
PubMed
Summary

Modern inflammatory bowel disease (IBD) therapy aims for disease modification, not just symptom relief. Achieving bowel healing with immunosuppression or biologics is key, with potential for probiotics to maintain remission.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.

Alimentary pharmacology & therapeutics·2018
Same author

Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.

Alimentary pharmacology & therapeutics·2017
Same author

Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation.

Alimentary pharmacology & therapeutics·2015
Same author

Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.

Alimentary pharmacology & therapeutics·2015
Same author

Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease.

Alimentary pharmacology & therapeutics·2015
Same author

Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.

Alimentary pharmacology & therapeutics·2015

Area of Science:

  • Gastroenterology
  • Immunology
  • Microbiology

Background:

  • Current inflammatory bowel disease (IBD) management focuses on disease modification and bowel healing.
  • Long-term bowel healing reduces hospitalizations and surgical interventions in IBD patients.
  • Immunosuppression and biologic therapies are primary treatments for achieving sustained mucosal healing.

Purpose of the Study:

  • To explore strategies for inducing and maintaining bowel healing in inflammatory bowel disease.
  • To address the timing of initiating aggressive therapies and the goal of early inflammation eradication.
  • To investigate the potential role of gut microbiota modulation, such as probiotics, in maintaining IBD remission.

Main Methods:

  • Review of current therapeutic approaches for inflammatory bowel disease, including immunosuppression and biologics.
  • Discussion of the need for predictive biomarkers (genetic and serologic) for disease course.
  • Exploration of the hypothesis that probiotics may aid in maintaining bowel healing post-induction therapy.

Main Results:

  • Immunosuppression and biologics are effective in achieving long-term bowel mucosal healing.
  • Optimal timing for initiating aggressive therapies and the concept of early eradication remain areas for investigation.
  • Probiotics are hypothesized to play a role in maintaining remission after initial treatment.

Conclusions:

  • Achieving and maintaining bowel healing is crucial for improving long-term outcomes in inflammatory bowel disease.
  • Personalized treatment strategies based on predictive markers are needed for early intervention.
  • Modulating the gut microbiome with probiotics may offer a novel approach for long-term maintenance therapy in IBD.

Related Experiment Videos